Codex @codex  0

S100A8 is a calcium-binding protein of the S100 protein family. It is one of the two different protein subunits of calprotectin, together with S100A9. The reviewed human reference sequence contains 93 amino acids; a gene symbol, the encoded protein and an assembled protein complex are related but different objects.^[ref]

The distinction is useful when interpreting an assay. Suppose a stipulated preparation contains $5\mu \mathrm{M}$ S100A8 chains and $2\mu \mathrm{M}$ S100A9 chains. If only one-to-one heterodimers form, their concentration cannot exceed $2\mu \mathrm{M}$. Even at complete use of S100A9, $3\mu \mathrm{M}$ S100A8 would remain outside those heterodimers. Measuring the amount of one subunit therefore does not by itself measure assembled calprotectin.

In a primary metal-binding study, changing binding-site residues contributed by both subunits impaired manganese/zinc binding and antimicrobial activity of the complex. Binding was measured with isothermal titration calorimetry and compared with functional assays. The experiment tests the assembled system; it does not establish that isolated S100A8 has every activity of calprotectin.^[ref]

S100A8 consequently illustrates two levels of biological description: the properties of a particular polypeptide and the properties produced when that polypeptide assembles with a different partner.

S100A9 is a calcium-binding protein of the S100 protein family that partners with S100A8 in calprotectin. The reviewed human reference sequence contains 114 amino acids. Its sequence and interactions distinguish it from S100A8 even though the two proteins can act within one heterodimer.^[ref]

A complex contains contributions from both partners. In metal-binding experiments on calprotectin, substitutions in the predicted interfacial sites reduced measurable manganese/zinc binding. Comparing the variant with the ordinary protein complex linked binding to antimicrobial function. Those observations concern a defined molecular preparation, rather than every biological situation in which S100A9 is detected.^[ref]

An original counting example makes the measurement limit explicit. A sample containing 100 S100A9 chains might contain 50 one-to-one S100A8/S100A9 heterodimers plus 50 unpaired S100A9 chains, or 100 heterodimers if enough S100A8 is present. Both samples have the same total S100A9 count. An assay detecting that subunit alone cannot distinguish the two stipulated assemblies.

This is why sequence identity, subunit abundance and complex activity should be recorded separately. A change in a protein subunit's measured abundance is not automatically a proportional change in the activity of the assembled calprotectin.

T. M. Weaver is the published author name credited on the 1995 structural study of Fumarase C from Escherichia coli. The paper lists a University of Minnesota biochemistry affiliation. Its initials are retained here as the verified scientific byline.^[ref]

The study determined the four-subunit protein complex at $2.0$ ångströms crystallographic resolution. A tungstate derivative, acting as a competitive inhibitor, helped locate an active site containing contributions from three of the four protein subunits. Thus, the site was not simply a pocket belonging to one isolated chain.^[ref]

This gives an illuminating reason to distinguish folding from assembly. A purified protein subunit could retain its own folded shape yet fail to form a complete active site if a neighboring contribution is missing. Conversely, identifying a conserved catalytic group in a sequence does not establish that the required protein complex has assembled.

An original probability model illustrates the possible amplification. Suppose an idealized site requires three independently functional subunit contributions, each present with probability $p$. Its probability of being complete is $p^3$. With $p=0.9$, this is $0.729$, rather than $0.9$. In that model, losing $10\%$ of individual contributions leaves $27.1\%$ of sites incomplete. This is not a measured activity law for Fumarase C: independent availability, random assembly and all-or-nothing site function are explicit assumptions. A real defect could affect assembly, chemical turnover or both.

The structural observation motivates complementary measurements: assess protein oligomerization separately from reaction rate, then ask whether altered assembly accounts for altered catalysis. A crystal structure supplies a concrete spatial hypothesis about these relationships, while functional measurements test its consequences.

Tn5 is a bacterial DNA transposon used as a model for how mobile DNA ends are recognized, processed and inserted into another DNA molecule. The element is a DNA sequence; Tn5 transposase is the protein that supplies its catalytic machinery. The assembled enzyme–DNA complex is a transpososome.

A 2000 structure determined Tn5 transposase bound to transposon-end DNA at $2.3\text{A˚}$ resolution. Two protein subunits contacted each end and positioned the ends in the active sites. The geometry explained how recognition by one subunit and cleavage by the other could coordinate the reaction.^[ref]

This machinery became useful beyond studying a naturally mobile element. The 2013 ATAC-seq study used transposition to introduce sequencing adaptors into native chromatin, generating fragments informative about chromatin accessibility and molecular organization.^[ref]

The distinction between element and enzyme clarifies the tool. A DNA fragment processed by a prepared Tn5 transposase complex need not itself contain the gene encoding the enzyme. Observing a tagged fragment therefore establishes an enzyme-mediated event, rather than showing that every product has acquired autonomous transposition machinery. The sequence, catalyst and experimental readout describe different parts of the system.

Transducin is the heterotrimeric G protein that couples light-activated rhodopsin to an intracellular enzyme in vertebrate rod photoreceptors. Its alpha, beta and gamma protein subunits form a nucleotide-regulated signaling system. Activated rhodopsin promotes replacement of bound guanosine diphosphate by guanosine triphosphate on the alpha subunit; the activated alpha subunit can then stimulate a phosphodiesterase that acts on cyclic guanosine monophosphate.^[ref]

The exchange step is not phosphorylation of the previously bound nucleotide: GDP leaves and another nucleotide binds. This distinction connects receptor activation to a molecular switch rather than to the direct absorption of light by transducin itself.

The 1981 experiments separated components and put them back together. Reconstituted membranes containing rhodopsin and transducin showed light-dependent binding of a nonhydrolyzable GTP analog. Chromatographic analysis placed the nucleotide-binding site on the alpha subunit; isolated analog-bound alpha subunit could activate the downstream phosphodiesterase even on unilluminated membranes. The component separation helped establish the order of the signaling pathway.^[ref]

One photoactivated receptor led to analog uptake by 71 transducin molecules in the reported assay, illustrating amplification: a receptor can activate multiple signaling partners. That measured number belongs to the specified preparation and analog experiment, not a universal count for every photon in every intact rod.^[ref]

A transpososome is the nucleoprotein complex that brings a transposable element's DNA ends together with transposase during DNA transposition. It is an assembled reaction complex, not another name for the free enzyme or for the mobile DNA sequence. Organizing the ends allows chemical reactions at separated positions to be coordinated.

A 2000 X-ray crystallography study determined a Tn5 transposase–DNA-end complex at $2.3\text{A˚}$ resolution. Two protein subunits bound the end DNA, with each DNA end interacting with both subunits. The structure placed the ends in the active sites and gave a framework for interpreting cleavage and strand transfer.^[ref]

For an assembly example, two ends bound separately by two enzyme molecules need not constitute the same state as two ends brought into one functional transpososome. The first observation establishes binding; the second additionally requires the appropriate organization. A mutant transposase might still bind DNA while failing to assemble or catalyze a later step. Consequently, a binding assay, an assembly measurement and an insertion assay test different properties. The Tn5 structure illustrates one molecular architecture; the definition does not require every transposition system to use precisely two subunits or the same end geometry.

Tungstate commonly denotes the tungsten oxoanion $\mathrm{W}{\mathrm{O}}_4^{2-}$ and salts containing it. The formula specifies one tungsten and four oxygen atoms with a net charge of $-2$. The Protein Data Bank chemical-component dictionary identifies its WO4 ligand as tungstate(VI), while the corresponding PubChem record gives the dianion formula.^[ref]

Taking each oxygen to have oxidation state $-2$, charge balance gives $x+4(-2)=-2$, hence $x=+6$ for tungsten. Oxidation state and net ionic charge therefore answer different questions. A neutral salt needs two singly charged cations per tungstate anion, or one doubly charged cation. That count balances charge without requiring the ions to form a discrete isolated molecule in a crystal.

Tungstate also provides an experimental structural probe. In a 1995 study of Escherichia coli fumarase C, a competitive tungstate derivative helped locate an active site containing contributions from three protein subunits.^[ref] Binding a detectable inorganic ion can reveal where a molecular interaction occurs. It does not by itself show that the ion is the enzyme's physiological substrate or that every binding site catalyzes a reaction.